tradingkey.logo

Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises

ReutersJan 11, 2026 10:05 PM

- Beam Therapeutics Inc BEAM.O:

  • BEAM THERAPEUTICS SETS STRATEGIC PRIORITIES FOR ITS GENETIC DISEASE AND HEMATOLOGY FRANCHISES TO DRIVE EXECUTION OF LATE-STAGE CLINICAL PROGRAMS AND EXTENDS ITS OPERATING RUNWAY THROUGH COMMERCIAL TRANSITION

  • BEAM THERAPEUTICS INC - FDA ALIGNMENT ON ACCELERATED APPROVAL PATHWAY FOR BEAM-302

  • BEAM THERAPEUTICS INC - RISTO-CEL BLA SUBMISSION EXPECTED BY YEAR-END 2026

  • BEAM THERAPEUTICS INC - TO ANNOUNCE NEW LIVER-TARGETED PROGRAM IN H1 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI